Event on

Hear expert opinion on the use of CRP point-of-care testing for COVID-19 management and reduction of antimicrobial resistance

Background

Join a panel of experts from across Europe for this compelling webinar presenting a view from the front line in Europe.

The webinar will analyse studies from around the world that show that C-reactive protein (CRP) levels proved to be one of the strongest inflammatory markers for severity and risk assessment in COVID-19 patients. [1] [2] [3] [4] [5]

The webinar will highlight the importance of Antibiotic Stewardship Programs (ASPs) in the context of the global pandemic and how antibiotics should be used only when necessary to curb the rise of antimicrobial resistance (AMR). [6] [7] [8] [9]

90% of respiratory tract infections (RTIs) are viral and therefore antibiotics have no clinical benefit. And yet RTIs are one of the most common reasons for unnecessary antibiotic prescribing. [10]

Learning Objectives

  • Despite the viral origin of COVID-19, a standard reflex by physicians is to start treatment with antibiotics since cough, fever and radiologic infiltrates are hallmarks of bacterial community-acquired pneumonia, which requires antibiotic treatment. [9]
  • The detection of CRP is of certain value to distinguish whether there is a bacterial infection in the lung. [6]
  • CRP may reflect disease severity and may be an independent predictor of adverse outcomes in COVID-19 patients. [1] [2] [3] [4] [5]
  • Antibiotics should be reserved for the patients with the most severe presentations. [9]
  • Avoid blind or inappropriate use of antibacterial drugs, especially the combination of broad-spectrum antibacterial drugs. [6]
  • There are many reasons why European countries launch Antibiotic Stewardship Programs (ASPs), and in the context of COVID-19, an ASP is needed now more than ever.

Le opinioni e le opinioni presentate sono solo degli autori. Il contenuto di questo webcast è destinato esclusivamente a scopi informativi/didattici.

Presentazioni

  • Prof. Nicholas Francis

    Prof. Nicholas Francis
    (UK)
    Chair

    Review and Learning outcomes. C-Reactive Protein point-of-care testing for safely reducing antibiotics for acute exarcerbations of chronic obstructive pulmonary disease: The findings of the PACE Study.

    English


    PhD, MD — Professor of Primary Care Research in the School of Primary Care, Population Sciences and Medical Education, University of Southampton, UK.

  • Dr. Carl Llor

    Dr. Carl Llor
    (Spain)
    Speaker

    Temperature checks alone cannot stop the spread of COVID-19 — how inflammatory markers can be used to support with patient assessment.

    English


    University Institute in Primary Care Research Jordi Gol, Via Roma Health Care Centre, Barcelona. Research Unit for General Practice. Department of Public Health, University of Copenhagen, Denmark.

  • Prof. Ivan Gentile

    Prof. Ivan Gentile
    (Italy)
    Speaker

    Severity assessment and outcome prediction in the COVID-19 patient.

    English


    Associate Professor of Infections Diseases, Director of the Residency Program of Infections & Tropical Diseases. Department of Clinical Medicine, Chief of the Infections Diseases Unit AOU Federico II, Naples, Italy.

  • Prof. Dag Berild

    Prof. Dag Berild
    (Norway)
    Speaker

    Antibiotic stewardship in the time of COVID-19 is vital — AMR still persists and could be heightened by the pandemic. Antibiotic treatment time period, how long is enough?

    English


    Md, PhD — Consultant and Professor Infectious Disease, University of Oslo & Oslo Metropolitan University, Norway.

  • Dr. Aggy York

    Dr. Aggy York
    (UK)
    Panelist

    Panel Discussion: POC CRP testing impact on antibiotic prescribind in Heywood, Middleton & Rochdale clinical comissioning group.

    English


    General Practitioner Rochdale, UK. Clinical Lead for Primary Care, Heywood, Middleton and Rochdale Clinical Comissioning Group, UK.


Le opinioni e le opinioni presentate sono solo degli autori. Il contenuto di questo webcast è destinato esclusivamente a scopi informativi/didattici.

  1. CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). April 3, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidancemanagement-patients.html#lab-findings
  2. Luo X, et al. medRxiv. Published online 2020. https://doi.org/10.1101/2020.03.21.20040360
  3. Tan C, et al. ORCID iD: 0000-0002-2522-4524.
  4. Wang L. Médecine et maladies infectieuses. 2020. https://doi.org/10.1016/j.medmal.2020.03.007
  5. Li H, et al. Journal of Infection. Published online 2020. https://doi.org/10.1016/j.jinf.2020.03.035
  6. Huttner B, et al. COVID-19: Don’t neglect antimicrobial stewardship: principles! Clinical Microbiology and Infection. 2020. https://doi.org/10.1016/j.cmi.2020.04.024
  7. Guan W, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20. doi:10.1056/NEJMoa2002032
  8. Rawson T, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;2:ciaa530. doi:10.1093/cid/ciaa530.32358954
  9. Jin YH, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research. 2020;7:4. https://doi.org/10.1186/s40779-020-0233-6
  10. Aabenhus R, et al. Cochrane Database of Systematic Reviews. 2014;11. Art. No.: CD010130.

© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only. 10006082-01